- Raised $10M convertible note, Mar 2016
- Raised $12M Series A, May 2008
- Raised $2.5M Series B, Apr 2021
About
TransAlgae develops an algae-based platform for the oral delivery of drugs (vaccines, immune modulators, insecticides, etc.) for human and animal health and for crop protection. TransAlgae's drug-delivery platform was demonstrated on mice as a model for humans. TransAlgae successfully demonstrated that proteins, expressed in algae, were orally delivered to the mice blood and liver in their intact form, due to the native bio-encapsulation of the algae and the formulation that TransAlgae has developed. In the area of animal health, TransAlgae's oral-delivery technology replaces the need for antibiotics and vaccination by injections. The company's algal powder, containing the desired drug or vaccine, is used as a feed supplement, enabling vaccination by feeding. TransAlgae has also developed a proprietary platform for the delivery of biological-based insecticides to be sprayed on crops. The technology enables targeting particular insects in a specific manner, replacing the need for toxic chemicals. The genetically modified algae are inactive, thus not affecting humans, animals, or crops, and are classified as a GMO-derived material.
Funding history · 6 rounds · $31.6M total
Headcount over time
Q&A
- What is TransAlgae's primary focus?
- TransAlgae develops an algae-based platform for the oral delivery of drugs such as vaccines, immune modulators, and insecticides for human and animal health, as well as for crop protection.
- When was TransAlgae founded?
- TransAlgae was founded in May 2008.
- What is the total amount of funding TransAlgae has raised to date?
- TransAlgae has raised a total of $31,581,080 USD.
- How many employees does TransAlgae currently have?
- TransAlgae has 11-50 employees.
- What is TransAlgae's primary sector?
- TransAlgae's primary sector is Health Tech & Life Sciences.
- Who are the co-founders of TransAlgae?
- The co-founders of TransAlgae are Maor Sasson, Doron Eisenstadt, and Ofra Chen.
- What is the core technology behind TransAlgae's drug delivery platform?
- TransAlgae's platform utilizes genetically modified algae for oral drug delivery, leveraging the native bio-encapsulation of algae and a proprietary formulation.
Team · 3
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| linkedin.com/company/627820 |
Identifiers & details
| Founded | 2008-5 |
|---|---|
| Employees (exact) | 17 |
Radar intelligence
Patents
| EPO | 16 |
|---|
Web history (Wayback)
| Domain | transalgae.com |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514134550 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2008-05-07 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2024 |
| Active charges / liens | 0 |
| Registry events | 1 — people (1) |
| Registered address | פקריס 2 רחובות |
Recent registry events
| Date | Event |
|---|---|
| 2025-08-10 | עדכון בעלי תפקידים |